Differences in clinicopathological characteristics and major prognostic factors between B-lymphoma and peripheral T-lymphoma excluding adult T-cell leukemia/lymphoma

Leuk Lymphoma. 1993 Jul;10(4-5):335-42. doi: 10.3109/10428199309148557.

Abstract

A total of 541 consecutive patients treated between 1975 and 1985, 449 with B-lymphoma and 92 with peripheral T-lymphoma, excluding adult T-cell leukemia/lymphoma (ATL), termed peripheral non-ATL T-lymphoma, were analysed. Clinicopathological features that were predominantly associated with B-lymphoma were low and intermediate grades (defined by the Working Formulation), diffuse large cell type, stage II disease, bulky disease, favourable extranodal sites that are defined as a group of primary tumors such as the eye, Waldeyer's ring, thyroid, and stomach, while other features predominantly associated with peripheral non-ATL T-lymphoma were high grade pathology, diffuse mixed-cell and immunoblastic type, systemic "B" symptoms, poor performance status (PS), generalized lymphadenopathy, involvement of organs such as liver, skin, and nose, leucocytosis, and a high levels of serum alkaline phosphatase. The survival curve for B-lymphoma was better (P < 0.01) than that for peripheral non-ATL T-lymphoma. Multivariate analysis revealed that the major prognostic factors were pathology, stage, and primary site for B-lymphoma, while stage, PS, and total protein levels were important for peripheral non-ATL T-lymphoma. These results indicate that B- and peripheral non-ATL T-lymphomas appear to have different biological characteristics.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / blood
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunophenotyping
  • Japan / epidemiology
  • Life Tables
  • Lymphoma, B-Cell / blood
  • Lymphoma, B-Cell / mortality*
  • Lymphoma, B-Cell / pathology
  • Lymphoma, B-Cell / therapy
  • Lymphoma, T-Cell, Peripheral / blood
  • Lymphoma, T-Cell, Peripheral / mortality*
  • Lymphoma, T-Cell, Peripheral / pathology
  • Lymphoma, T-Cell, Peripheral / therapy
  • Male
  • Middle Aged
  • Neoplasm Proteins / blood
  • Neoplasm Staging
  • Prognosis
  • Proportional Hazards Models
  • Survival Analysis

Substances

  • Biomarkers, Tumor
  • Neoplasm Proteins